News about "Pfizer"

US FDA Approves Pfizer's Ibrance for Maintenance Treatment of HR+, HER2+ Metastatic Breast Cancer

FDA approval makes Ibrance the first CDK4/6 inhibitor indicated for HR+ metastatic breast cancer regardless of HER2 status.

Pfizer | 26/06/2026 | By News Bureau |  244

US FDA Approves Pfizer's HYMPAVZI for Treatment of Additional Hemophilia A and B Patients

Pfizer’s HYMPAVZI has received expanded US FDA approval for hemophilia A and B patients aged 12 years and older with inhibitors, as well as children aged 6-11 years with or without inhibitors. The approval makes HYMPAVZI the first subcutaneous non-factor therapy available for pediatric hemophilia B patients ages 6 to 11 years old.

Pfizer | 09/06/2026 | By News Bureau

Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing

Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.

Pfizer | 08/06/2026 | By News Bureau

Pfizer's BRAFTOVI Nearly Doubles Progression-Free Survival in Metastatic Colorectal Cancer

Pfizer reported phase 3 BREAKWATER trial results showing that the BRAFTOVI regimen nearly doubled median Progression-Free Survival (PFS) in patients with metastatic colorectal cancer, reducing the risk of disease progression or death by 56 percent and the risk of death by 44 percent compared with standard chemotherapy in BRAF V600E-mutant disease.

Pfizer | 01/06/2026 | By News Bureau

Pfizer's LORBRENA Delivers 7-Year Progression-Free Survival in Advanced NSCLC

Pfizer reported 7-year results from the CROWN trial showing that LORBRENA achieved the longest Progression-Free Survival reported to date in advanced Non-Small Cell Lung Cancer (NSCLC), with 55 percent of patients remaining progression-free at 7 years and median progression-free survival not yet reached.

Pfizer | 30/05/2026 | By News Bureau |  173

Pfizer and Innovent Biologics Partner to Advance Global Oncology Drug Development

Pfizer and Innovent Biologics have entered a global strategic collaboration to develop innovative oncology medicines, combining 12 discovery and early-stage programs to accelerate cancer drug development through shared research, clinical development, and commercialisation efforts.

Pfizer | 29/05/2026 | By News Bureau |  112

Pfizer Reports Positive Phase 2 Results for Pediatric Pneumococcal Vaccine Program

Pfizer reports strong phase 2 results for its 25-valent pediatric pneumococcal vaccine candidate, showing enhanced serotype 3 immune response, broad protection across 25 serotypes, and a favorable safety profile ahead of Phase 3 development.

Pfizer | 20/05/2026 | By News Bureau |  120

Pfizer's ELREXFIO Boosts Progression-Free Survival in Relapsed Multiple Myeloma

Pfizer’s ELREXFIO meets primary endpoint in MagnetisMM-5, showing significant progression-free survival benefit in relapsed/refractory multiple myeloma, with consistent safety and ongoing evaluation of Overall Survival (OS).

Pfizer | 01/05/2026 | By News Bureau

Pfizer Reaches Three Settlement Deals for VYNDAMAX

Pfizer reaches three settlement agreements for VYNDAMAX, extending US patent exclusivity to June 1, 2031, subject to the outcome of other litigation.

Pfizer | 30/04/2026 | By News Bureau |  213

Pfizer-Valneva Lyme Vaccine Shows Strong Phase-III Efficacy

Pfizer and Valneva’s Lyme disease vaccine candidate showed over 70 percent efficacy in phase-III trials in individuals aged five years and above, with a strong safety profile, as Pfizer prepares for regulatory submissions, marking a key step towards potential approval.

Pfizer | 24/03/2026 | By News Bureau